Today: 10 June 2026
BILL stock slides 7% to start 2026 despite KBW target raise — what to watch Monday
4 January 2026
2 mins read

BILL stock slides 7% to start 2026 despite KBW target raise — what to watch Monday

NEW YORK, Jan 4, 2026, 11:01 AM ET — Market closed

  • BILL shares ended Friday down 7.3% at $50.56, setting up a test when U.S. markets reopen Monday.
  • Keefe, Bruyette & Woods lifted its price target to $60 while keeping a “market perform” rating, Benzinga data showed.
  • Next catalysts include a Jan. 16 finance leadership change disclosed in an SEC filing and an earnings update expected in early February.

BILL Holdings, Inc. (NYSE: BILL) shares closed down 7.3% on Friday at $50.56, a sharp drop that left the small-business payments and software name on watchlists ahead of Monday’s reopening. The move came even as Keefe, Bruyette & Woods raised its price target.

The slide matters now because it was one of the stock’s biggest single-day declines in weeks and pushed BILL back toward the lower end of its recent trading band. With the new year starting on a choppy note for growth stocks, investors are looking for clearer signals on interest rates and small-business spending — two inputs that can quickly swing fintech valuations.

It also leaves BILL trading roughly halfway below its 52-week high, underscoring how quickly sentiment can turn on software names tied to transaction activity. The stock’s 52-week range stands at about $36.55 to $100.19, according to market data.

On Friday, BILL opened near $55 and traded as low as about $50.5 before settling near the session low. About 3.6 million shares changed hands, according to LSEG data.

The broader tape did not offer much support. The S&P 500 ended Friday up 0.19% while the Nasdaq finished essentially flat, a session marked by higher Treasury yields and a rotation toward value.

“Value is outperforming growth,” said Jed Ellerbroek, a portfolio manager at Argent Capital, in a Reuters interview, capturing a backdrop that tends to pressure higher-multiple software stocks. Reuters market report

Against that setting, Sanjay Sakhrani at Keefe, Bruyette & Woods raised his price target on BILL to $60 from $52 and kept a “market perform” rating, Benzinga’s analyst ratings feed showed. Benzinga analyst ratings

A “price target” is an analyst’s estimate of where a stock could trade over the next year, while “market perform” is Wall Street shorthand for a roughly neutral view — not a call to buy aggressively, but not a warning to sell.

BILL sells cloud-based tools that help small and midsize businesses automate payables and receivables — the routine work of sending, receiving and tracking payments. The company’s results tend to track how much money moves through its platform and how well it holds onto customers in a tight spending environment.

The next major company catalyst is its quarterly update, with several market calendars pointing to an early-February report; Nasdaq’s earnings page currently shows an estimated Feb. 5 date. Investors will be listening for commentary on payment volumes, customer growth and outlook for 2026.

Before that, investors also have a mid-January management change to parse. The company’s principal accounting officer, Germaine Cota, plans to resign effective Jan. 16, an SEC filing showed.

But the risk for bulls is that rising yields and any signs of slowing small-business activity could hit payment volumes and keep pressure on software valuations. If BILL’s next update disappoints, the stock could quickly drift back toward its 52-week low area.

Stock Market Today

  • UiPath Shares Fall as Investors Question AI Automation Growth
    June 10, 2026, 9:47 AM EDT. UiPath's (PATH) stock dropped 3.76% to $10.75 amid investor doubts about the speed of its AI automation-driven recurring revenue growth. Despite a 17% year-over-year boost in first-quarter revenue to $418 million and annual recurring revenue (ARR) rising 12% to $1.901 billion, concerns linger over slower ARR acceleration. The company forecasted second-quarter ARR between $1.929 billion and $1.934 billion, implying a slowdown in new ARR additions from $49 million to around $30.5 million. CEO Daniel Dines highlighted progress in AI agentic products moving from pilot to production, supported by first-quarter GAAP profitability. However, investors remain cautious, treating UiPath as a 'show me' stock amid broader tech sector declines, as the focus shifts to growth acceleration in AI-enabled automation platforms.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings
Previous Story

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop